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events (VTE) in immobilized acutely ill general medical
inpatients from the hospital perspective in Germany.
METHODS: The incremental cost-effectiveness ratios
“additional cost for ENOX per clinical VTE averted
versus NPP” and “additional cost for ENOX per episode
of severe bleeding (ESB) averted versus UFH” were quan-
tiﬁed using a modelling approach based on decision-tree
technique. Resource use during thromboprophylaxis,
diagnosis, and treatment was collected from a hospital
survey. Costs were exclusively those to hospitals and were
determined by multiplying utilised resource items by the
price or tariff of each item. Clinical effectiveness was
taken from the MEDENOX [Samama et al. NEJM 1999]
and Thromboembolism-Prevention in Cardiac or Respi-
ratory Disease With Enoxaparin [Kleber et al. Am Heart
J 2003] trials and from a meta-analysis [Mismetti et al.
Thromb Haemost 2000]. The evaluation encompassed 8
(6–14) days of thromboprophylaxis plus time to treat
VTE and ESB in hospital. RESULTS: The base-case analy-
sis revealed incremental cost of €1543 for ENOX per clin-
ical VTE averted versus NPP, whereas ENOX dominated
UFH. In comprehensive sensitivity analyses, using impact
analysis and Monte Carlo simulation, the robustness of
the model was shown. In no case had the price of ENOX
the main impact on cost effectiveness. In 95% of 10,000
simulation steps, incremental cost for ENOX ranged
between €201 and 4 €154 per clinical VTE averted versus
NPP. In 91% of 10,000 simulation steps, ENOX
remained dominant over UFH. CONCLUSIONS: In
acutely ill general medical inpatients, ENOX offers 
hospitals in Germany a highly cost-effective thrombo-
prophylaxis compared to NPP and an enormous saving
potential when used instead of UFH.
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OBJECTIVES: Cardiovascular death is an important
endpoint in clinical trials. In health-economic analyses it
also plays a key role in the calculation of the number of
life years gained. Unlike other outcomes like myocardial
infarction (MI) or stroke, not much research has been
done on the assessment of speciﬁc resource use in patients
dying of a cardiovascular cause. This study assessed the
cost of cardiovascular death in Belgium. METHODS: In
this cost-of-illness study, data on resource utilisation were
retrospectively collected in patients with a history of MI
who died in the hospital in the year 2002. Four hospitals
were selected based on setting (community-university)
and geographical region (north and south). Direct
medical costs from the health care payer’s perspective, as
expressed by the intensity of medical resource consump-
tion in physical units, times the direct cost or charge per
unit, were considered. Costs were deﬁned as cost of hos-
pitalisation (basic care and nursing), drug use, diagnostic
tests, physician consults and technical interventions.
RESULTS: The charts of 60 patients were reviewed (mean
age: 76 ± 11 years). The average length of stay was 5.28
days (St. Err. 0.64). The main causes of death were MI
(37%), cardiogenic shock (22%) and ventricular ﬁbrilla-
tion (20%). The average hospitalisation cost €2045 (St.
Err. €215), the drug cost €383 (St. Err. €97), the cost of
diagnostic tests €344 (St. Err. €42), the cost of physician
consults €29 (St. Err. €7) and the cost of technical inter-
ventions €943 (St. Err. €207), resulting in a total cost 
of death from cardiovascular disease of €3744 (St. Err.
€431). In the Northern part the average cost is about
€1000 higher compared to the Southern part (€4284 vs.
€3239) (NS). CONCLUSIONS: Cardiovascular death 
is not only an important clinical endpoint but also an
important economic parameter due to its high cost.
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OBJECTIVE: Results from the Clopidogrel in Unstable
Angina to Prevent Recurrent Events (CURE) study
showed that clopidogrel plus aspirin, comparing to
aspirin alone, reduced the cardiovascular events (death,
myocardial infarction, and stroke) in patients with acute
coronary syndromes (ACS). Yet the acquisition cost of
clopidogrel is much higher. It would therefore be worth-
while to compare the long term cost impact of these 2
regimens. METHODS: Until recently, only very few
patients with ACS received a clopidogrel-aspirin combi-
nation therapy in Hong Kong. Therefore a hypothetical
cohort was formed and compared to a real group of
patients treated with aspirin alone. For the aspirin group,
medical history was reviewed and cardiovascular and gas-
trointestinal events occurring in a period of 12 months
after initiation of therapy were recorded. The target cost
items included hospitalisation, emergency room visits,
outpatient clinic visits, related medications, diagnostic
tests, procedures and surgery. For the hypothetical
cohort, the probabilities/relative risks for clinical events
were adopted from the CURE study. The unit cost of
drugs and other resource items were based on the Hong
Kong Hospital Authority drug acquisition cost 2001 and
Hong Kong Government Gazette 2003 respectively. The
perspective of the study was that of a public health organ-
isation. RESULTS: Fifty-four consecutive patients with
ACS receiving aspirin therapy were identiﬁed over the
period of January 1, 2001 to December 31, 2001 from 
a major public hospital in Hong Kong and studied. 
